Ge Long Hui A P P·2025-11-26 07:42Core Viewpoint - The performance of Tigermed's Q3 2025 results met expectations, with short-term pressure on revenue and gross margin due to multiple factors [1] Group 1: Financial Performance - In the first three quarters, the clinical operations business faced challenges, leading to short-term pressure on revenue and gross margin [1] - The net new signed orders maintained good growth in the first three quarters, indicating a positive trend in order acquisition and conversion [1] - Q3 2025 showed an improvement trend in both revenue and profit on a quarter-on-quarter basis [1] Group 2: Future Outlook - The company is expected to benefit from the development opportunities in the new industry cycle, potentially gaining more high-quality customer orders [1] - The overseas clinical business is anticipated to see further growth [1] - Continuous efforts in cost reduction and efficiency enhancement, along with the application of AI technology, are expected to improve profit margins once order prices recover [1] Group 3: Industry Position - As a leading company in the domestic clinical CRO industry, Tigermed is likely to continue benefiting from the recovery in industry demand [1] - The company maintains a "buy" rating based on its strong market position and growth prospects [1]